

# Kenneth Blum

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/826722/publications.pdf>

Version: 2024-02-01

243  
papers

10,493  
citations

34105

52  
h-index

40979

93  
g-index

247  
all docs

247  
docs citations

247  
times ranked

5821  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 552.	2.6	7
2	The long-term interaction of diet and dopamine D2 gene expression on brain microglial activation. <i>Psychiatry Research - Neuroimaging</i> , 2022, 320, 111430.	1.8	3
3	Development and validation of the Reward Deficiency Syndrome Questionnaire (RDSQ-29). <i>Journal of Psychopharmacology</i> , 2022, 36, 409-422.	4.0	14
4	Chronic treatment and abstinence from methylphenidate exposure dose-dependently changes glucose metabolism in the rat brain. <i>Brain Research</i> , 2022, 1780, 147799.	2.2	6
5	Neurogenetics of alcohol use disorder a subset of reward deficiency syndrome: candidate genes to be or not to be?. , 2022, , 105-160.		0
6	Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowing in the Wind"? <i>Journal of Personalized Medicine</i> , 2022, 12, 321.	2.5	15
7	Frequency of the Dopamine Receptor D3 (rs6280) vs. Opioid Receptor $\mu$ 1 (rs1799971) Polymorphic Risk Alleles in Patients with Opioid Use Disorder: A Preponderance of Dopaminergic Mechanisms?. <i>Biomedicine</i> , 2022, 10, 870.	3.2	5
8	The Reward Deficiency Syndrome and Links with Addictive and Related Behaviors. , 2022, , 1-16.		6
9	Overcoming reward deficiency syndrome by the induction of "dopamine homeostasis" instead of opioids for addiction: illusion or reality?. <i>Journal of Osteopathic Medicine</i> , 2022, .	0.8	4
10	Proposing a "Brain Health Checkup (BHC)" as a Global Potential "Standard of Care" to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of "Dopamine Homeostasis". <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5480.	2.6	4
11	FOXP3 and GDNF Polymorphisms as Common Genetic Factors of Substance Use and Addictive Behaviors. <i>Journal of Personalized Medicine</i> , 2022, 12, 690.	2.5	10
12	Brain Mapping the Effects of Chronic Aerobic Exercise in the Rat Brain Using FDG PET. <i>Journal of Personalized Medicine</i> , 2022, 12, 860.	2.5	6
13	Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6395.	2.6	6
14	Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation. <i>Journal of Personalized Medicine</i> , 2022, 12, 1009.	2.5	6
15	Understanding that Addiction Is a Brain Disorder Offers Help and Hope. <i>Health</i> , 2022, 14, 684-695.	0.3	2
16	Psychostimulant use disorder emphasizing methamphetamine and the opioid -dopamine connection: Digging out of a hypodopaminergic ditch. <i>Journal of the Neurological Sciences</i> , 2021, 420, 117252.	0.6	22
17	Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) during Adolescent Brain Development. <i>Current Psychopharmacology</i> , 2021, 10, 181-196.	0.3	13
18	Meet Our Editor-in-Chief. <i>Current Psychopharmacology</i> , 2021, 10, 3-3.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Epigenetic Repair of Terrifying Lucid Dreams by Enhanced Brain Reward Functional Connectivity and Induction of Dopaminergic Homeo - static Signaling. <i>Current Psychopharmacology</i> , 2021, 10, 170-180.	0.3	5
20	Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis. <i>Frontiers in Psychiatry</i> , 2021, 12, 623403.	2.6	16
21	High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial. <i>Molecular Neurobiology</i> , 2021, 58, 3335-3346.	4.0	21
22	A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration. <i>Journal of Personalized Medicine</i> , 2021, 11, 212.	2.5	15
23	Endorphinergic Enhancement Attenuation of Post-traumatic Stress Disorder (PTSD) via Activation of Neuro-immunological Function in the Face of a Viral Pandemic. <i>Current Psychopharmacology</i> , 2021, 10, 86-97.	0.3	4
24	Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise. <i>Current Psychopharmacology</i> , 2021, 10, 123-137.	0.3	2
25	Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9774.	2.6	5
26	Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11529.	2.6	12
27	Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality?. <i>Acta Scientific Neurology</i> , 2021, 4, 17-24.	0.1	2
28	Psychoactive Drugs Like Cannabis -Induce Hypodopaminergic Anhedonia and Neuropsychological Dysfunction in Humans: Putative Induction of Dopamine Homeostasis via Coupling of Genetic Addiction Risk Severity (GARS) testing and Precision Pro-dopamine Regulation (KB220). , 2021, 13, 86-92.		0
29	Translational and Molecular Cytoarchitectural Genetic Guided Therapy to Induce Dopamine Homeostatic Neuro-signaling in Reward Deficiency and Associated Drug and Behavioral Addiction Seeking: A 60 Year Sojourn the Future is Now. , 2021, 10, 1-4.		0
30	A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management". <i>Psychology Research and Behavior Management</i> , 2021, Volume 14, 2115-2134.	2.8	7
31	Neurobiology and Spirituality in Addiction Recovery.. <i>Acta Scientific Neurology</i> , 2021, 4, 64-71.	0.1	1
32	Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117137.	0.6	32
33	Precision Behavioral Management (PBM): A Novel Genetically Guided Therapy to Combat Reward Deficiency Syndrome (RDS) Relevant to the Opiate Crisis. , 2020, , 297-306.		43
34	Putative COVID- 19 Induction of Reward Deficiency Syndrome (RDS) and Associated Behavioral Addictions with Potential Concomitant Dopamine Depletion: Is COVID-19 Social Distancing a Double Edged Sword?. <i>Substance Use and Misuse</i> , 2020, 55, 2438-2442.	1.4	16
35	In Search of Reward Deficiency Syndrome (RDS)-Free Controls: The "Holy Grail" in Genetic Addiction Risk Testing. <i>Current Psychopharmacology</i> , 2020, 9, 7-21.	0.3	18
36	Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS). <i>Journal of the Neurological Sciences</i> , 2020, 411, 116733.	0.6	27

#	ARTICLE	IF	CITATIONS
37	Administration of a putative pro-dopamine regulator, a neuronutrient, mitigates alcohol intake in alcohol-preferring rats. <i>Behavioural Brain Research</i> , 2020, 385, 112563.	2.2	23
38	Pre-clinical models of reward deficiency syndrome: A behavioral octopus. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 115, 164-188.	6.1	26
39	The therapeutic potential of exercise for neuropsychiatric diseases: A review. <i>Journal of the Neurological Sciences</i> , 2020, 412, 116763.	0.6	23
40	Co-occurrences of substance use and other potentially addictive behaviors: Epidemiological results from the Psychological and Genetic Factors of the Addictive Behaviors (PGA) Study. <i>Journal of Behavioral Addictions</i> , 2020, 9, 272-288.	3.7	56
41	Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual. <i>Journal of Systems and Integrative Neuroscience</i> , 2020, 6, .	0.6	10
42	Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency. <i>Journal of Addiction Science</i> , 2020, 06, .	0.5	7
43	Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family Affair. <i>Current Pharmaceutical Biotechnology</i> , 2020, 21, 528-541.	1.6	42
44	Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine. <i>Current Neuropharmacology</i> , 2020, 18, 578-595.	2.9	26
45	Hypothesizing High Negative Emotionality as a Function of Genetic Addiction Risk Severity (GARS) Testing in Alcohol Use Disorder (AUD). <i>Journal of Systems and Integrative Neuroscience</i> , 2020, 7, .	0.6	5
46	Polygenic and multi locus heritability of alcoholism: Novel therapeutic targets to overcome psychological deficits. <i>Journal of Systems and Integrative Neuroscience</i> , 2020, 7, .	0.6	2
47	Transmodulation of Dopaminergic Signaling to Mitigate Hypodopaminergia and Pharmaceutical Opioid-induced Hyperalgesia. <i>Current Psychopharmacology</i> , 2020, 9, 164-184.	0.3	0
48	Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency. , 2020, 6, 1-4.		2
49	In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing. <i>Current Psychopharmacology</i> , 2020, 9, 7-21.	0.3	7
50	Hypothesizing Major Depression as a Subset of Reward Deficiency Syndrome (RDS) Linked to Polymorphic Reward Genes: Considerations for Translational Medicine Approaches for Future Drug Development. <i>Handbook of Behavioral Neuroscience</i> , 2019, , 419-426.	0.7	0
51	Understanding the Scientific Basis of Post-traumatic Stress Disorder (PTSD): Precision Behavioral Management Overrides Stigmatization. <i>Molecular Neurobiology</i> , 2019, 56, 7836-7850.	4.0	23
52	Opioid Substitution Therapy: Achieving Harm Reduction While Searching for a Prophylactic Solution. <i>Current Pharmaceutical Biotechnology</i> , 2019, 20, 180-182.	1.6	59
53	Rapid Anti-Depressant Relief by Ketamine: Exploring A Complex Mechanism of Action. <i>Current Psychopharmacology</i> , 2019, 8, 99-112.	0.3	2
54	Death by Opioids: Are there non-addictive scientific solutions?. <i>Journal of Systems and Integrative Neuroscience</i> , 2019, 5, .	0.6	16

#	ARTICLE	IF	CITATIONS
55	A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone. <i>Substance Use and Misuse</i> , 2018, 53, 220-229.	1.4	66
56	Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD. <i>Journal of Behavioral Addictions</i> , 2018, 7, 192-203.	3.7	15
57	The DRD2 Taq1A A1 Allele May Magnify the Risk of Alzheimer's in Aging African-Americans. <i>Molecular Neurobiology</i> , 2018, 55, 5526-5536.	4.0	20
58	Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis. <i>Biomedical Journal of Scientific &amp; Technical Research</i> , 2018, 2, 1-4.	0.1	70
59	The Food and Drug Addiction Epidemic: Targeting Dopamine Homeostasis. <i>Current Pharmaceutical Design</i> , 2018, 23, 6050-6061.	1.9	40
60	Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors. <i>Frontiers in Psychiatry</i> , 2018, 9, 548.	2.6	53
61	Conceptualizing Addiction From an Osteopathic Perspective: Dopamine Homeostasis. <i>Journal of Osteopathic Medicine</i> , 2018, 118, 115-118.	0.8	52
62	Genetic addiction risk score GARS trade a predictor of vulnerability to opioid dependence. <i>Frontiers in Bioscience - Elite</i> , 2018, 10, 175-196.	1.8	92
63	Molecular role of dopamine in anhedonia linked to reward deficiency syndrome RDS and anti-reward systems. <i>Frontiers in Bioscience - Scholar</i> , 2018, 10, 309-325.	2.1	111
64	Hoehn and Yahr staging of Parkinson's disease in relation to neuropsychological measures. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 1370-1379.	3.0	16
65	Our evolved unique pleasure circuit makes humans different from apes: Reconsideration of data derived from animal studies. <i>Journal of Systems and Integrative Neuroscience</i> , 2018, 4, .	0.6	17
66	The benefits of genetic addiction risk score (GARS®) and pro-dopamine regulation in combating suicide in the American Indian population. <i>Journal of Systems and Integrative Neuroscience</i> , 2018, 4, .	0.6	10
67	The Benefits of Genetic Addiction Risk Score (GARS,®) Testing in Substance Use Disorder (SUD). <i>International Journal of Genomics and Data Mining</i> , 2018, 03, .	0.1	9
68	Genetic Addiction Risk Score (GARS) as a Predictor of Substance Use Disorder: Identifying Predisposition Not Diagnosis. , 2018, 1, .		10
69	Buprenorphine and Naloxone Combinations and Dopamine. <i>Current Psychopharmacology</i> , 2018, 6, .	0.3	0
70	The Benefits of Genetic Addiction Risk Score (GARS) Testing in Substance Use Disorder (SUD). <i>International Journal of Genomics and Data Mining</i> , 2018, 2018, .	0.1	7
71	Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse. , 2018, 7, 564-579.		7
72	Precision Behavioral Management (PBM) A Novel Approach to Combat Post-Traumatic Stress Disorder (PTSD). <i>SOJ Psychology</i> , 2018, 5, .	0.3	1

#	ARTICLE	IF	CITATIONS
73	Hypothesizing Music Intervention Enhances Brain Functional Connectivity Involving Dopaminergic Recruitment: Common Neuro-correlates to Abusable Drugs. <i>Molecular Neurobiology</i> , 2017, 54, 3753-3758.	4.0	22
74	Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutamatergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS). <i>Substance Use and Misuse</i> , 2017, 52, 535-547.	1.4	62
75	Substance use disorder a bio-directional subset of reward deficiency syndrome. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 1534-1548.	3.0	21
76	Dopamine homeostasis brain functional connectivity in reward deficiency syndrome. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 669-691.	3.0	88
77	BARHL1 Is Downregulated in Alzheimer's Disease and May Regulate Cognitive Functions through ESR1 and Multiple Pathways. <i>Genes</i> , 2017, 8, 245.	2.4	57
78	Neurogenetics of acute and chronic opiate opioid abstinence treating symptoms and the cause. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 1247-1288.	3.0	12
79	Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z. <i>PLoS ONE</i> , 2017, 12, e0174774.	2.5	92
80	Lyme and dopaminergic function: Hypothesizing reduced reward deficiency symptomatology by regulating dopamine transmission. <i>Journal of Systems and Integrative Neuroscience</i> , 2017, 3, .	0.6	8
81	Improvement of long-term memory access with a pro-dopamine regulator in an elderly male: Are we targeting dopamine tone?. <i>Journal of Systems and Integrative Neuroscience</i> , 2017, 3, .	0.6	6
82	The effects of residential dual diagnosis treatment on alcohol abuse. <i>Journal of Systems and Integrative Neuroscience</i> , 2017, 3, .	0.6	47
83	"Dopamine homeostasis" requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America's drug epidemic. <i>Journal of Systems and Integrative Neuroscience</i> , 2017, 3, .	0.6	14
84	Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)., 2017, 03, .		12
85	Pharmacological Inhibition of Brain Fatty Acid Binding Protein Reduces Ethanol Consumption in Mice., 2017, 03, .		10
86	Hypothesizing Las Vegas and Sutherland Springs Mass Shooters Suffer from Reward Deficiency Syndrome: "Born Bad", 2017, 03, 28-31.		4
87	Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD). <i>Global Journal of Addiction &amp; Rehabilitation Medicine</i> , 2017, 1, .	0.1	56
88	Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape. <i>Current Neuropharmacology</i> , 2017, 15, 184-194.	2.9	87
89	Critical Analysis of White House Anti-Drug Plan. <i>Global Journal of Addiction &amp; Rehabilitation Medicine</i> , 2017, 1, .	0.1	3
90	Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)., 2017, 3, 3-13.		7

#	ARTICLE	IF	CITATIONS
91	Physical Exercise Interventions for Drug Addictive Disorders. , 2017, 3, 17-20.		3
92	Pharmacological Inhibition of Brain Fatty Acid Binding Protein Reduces Ethanol Consumption in Mice. , 2017, 3, 21-27.		3
93	GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM): LESSONS LEARNED FROM AMERICA. Precision Medicine, 2017, 2, 17-22.	3.5	11
94	KB220Z, a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit?. , 2016, 2, 3-13.		29
95	Pilot clinical observations between food and drug seeking derived from fifty cases attending an eating disorder clinic. Journal of Behavioral Addictions, 2016, 5, 533-541.	3.7	12
96	The Psychoactive Designer Drug and Bath Salt Constituent MDPV Causes Widespread Disruption of Brain Functional Connectivity. Neuropsychopharmacology, 2016, 41, 2352-2365.	5.4	66
97	Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?. Substance Use and Misuse, 2016, 51, 1674-1679.	1.4	13
98	Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term. , 2016, 2, 14-21.		56
99	Dopamine D2 gene expression interacts with environmental enrichment to impact lifespan and behavior. Oncotarget, 2016, 7, 19111-19123.	1.8	29
100	Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake. Clinical Medical Reviews and Case Reports, 2016, 3, .	0.1	7
101	Hypothesizing that a Pro-Dopaminergic Regulator (KB220Z, Liquid Variant) can Induce "Dopamine Homeostasis" and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence. Clinical Medical Reviews and Case Reports, 2016, 3, .	0.1	12
102	Hypothesizing Molecular Genetics of the Holocaust: Were Dopaminergic Genes Involved or Brain Wash?. SOJ Psychology, 2016, 3, 1-5.	0.3	4
103	Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity. Current Pharmaceutical Design, 2016, 22, 5837-5854.	1.9	11
104	Low-Resolution Electromagnetic Tomography (LORETA) of changed Brain Function Provoked by Pro-Dopamine Regulator (KB220Z) in one Adult ADHD case. Open Journal of Clinical & Medical Case Reports, 2016, 2, .	1.0	11
105	THE BENEFITS OF CUSTOMIZED DNA DIRECTED NUTRITION TO BALANCE THE BRAIN REWARD CIRCUITRY AND REDUCE ADDICTIVE BEHAVIORS. Precision Medicine, 2016, 1, 18-33.	3.5	10
106	Putative dopamine agonist (KB220Z) attenuates lucid nightmares in PTSD patients: Role of enhanced brain reward functional connectivity and homeostasis redeeming joy. Journal of Behavioral Addictions, 2015, 4, 106-115.	3.7	39
107	miRegulome: a knowledge-base of miRNA regulomics and analysis. Scientific Reports, 2015, 5, 12832.	3.3	12
108	Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics. Cureus, 2015, 7, e348.	0.5	14



#	ARTICLE	IF	CITATIONS
109	Evoked Potentials and Memory/Cognition Tests Validate Brain Atrophy as Measured by 3T MRI (NeuroQuant) in Cognitively Impaired Patients. PLoS ONE, 2015, 10, e0133609.	2.5	8
110	NIDA-Drug Addiction Treatment Outcome Study (DATOS) Relapse as a Function of Spirituality/Religiosity. Journal of Reward Deficiency Syndrome, 2015, 01, 36-45.	1.0	35
111	Neurogenetics and gene therapy for reward deficiency syndrome: are we going to the Promised Land?. Expert Opinion on Biological Therapy, 2015, 15, 973-985.	3.1	23
112	Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility. Addiction Genetics, 2015, 2, 1-5.	0.5	6
113	Neurogenetic and Epigenetic Correlates of Adolescent Predisposition to and Risk for Addictive Behaviors as a Function of Prefrontal Cortex Dysregulation. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 286-292.	1.3	49
114	Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?. Molecular Neurobiology, 2015, 52, 1862-1869.	4.0	66
115	fMRI effects of KB220Z on neural pathways in reward circuitry of abstinent genotyped heroin addicts. Postgraduate Medicine, 2015, 127, 232-241.	2.0	135
116	A Shared Molecular and Genetic Basis for Food and Drug Addiction. Psychiatric Clinics of North America, 2015, 38, 419-462.	1.3	23
117	Reward Deficiency Syndrome: Attentional/Arousal Subtypes, Limitations of Current Diagnostic Nosology, and Future Research. Journal of Reward Deficiency Syndrome, 2015, 01, 6-9.	1.0	12
118	Enhancing Brain Pregnenolone May Protect Cannabis Intoxication but Should Not Be Considered as an Anti-addiction Therapeutic: Hypothesizing Dopaminergic Blockade and Promoting Anti-Reward. Journal of Reward Deficiency Syndrome, 2015, 01, 20-23.	1.0	9
119	Using the Neuroadaptagen KB200Z to Ameliorate Terrifying, Lucid Nightmares in RDS Patients: the Role of Enhanced, Brain-Reward, Functional Connectivity and Dopaminergic Homeostasis. Journal of Reward Deficiency Syndrome, 2015, 01, 24-35.	1.0	31
120	The Molecular Neurobiology of Twelve Steps Program & Fellowship: Connecting the Dots for Recovery. Journal of Reward Deficiency Syndrome, 2015, 01, 46-64.	1.0	72
121	Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction. Journal of Reward Deficiency Syndrome, 2015, 01, 65-68.	1.0	16
122	Coupling Neurogenetics (GARS) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms. Journal of Reward Deficiency Syndrome, 2015, 1, 75-80.	1.0	17
123	Addiction Treatment in America: After Money or Aftercare?. Journal of Reward Deficiency Syndrome, 2015, 01, 87-94.	1.0	14
124	Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction. Journal of Reward Deficiency Syndrome, 2015, 01, 95-104.	1.0	83
125	Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality. Clinical Medical Reviews and Case Reports, 2015, 2, .	0.1	11
126	Can Genetic Testing Provide Information to Develop Customized Nutrigenomic Solutions for Reward Deficiency Syndrome?. Clinical Medical Reviews and Case Reports, 2015, 2, .	0.1	4



#	ARTICLE	IF	CITATIONS
127	Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics.. <i>Cureus</i> , 2015, 7, e290.	0.5	5
128	Systematic Evaluation of "Compliance" to Prescribed Treatment Medications and "Abstinence" from Psychoactive Drug Abuse in Chemical Dependence Programs: Data from the Comprehensive Analysis of Reported Drugs. <i>PLoS ONE</i> , 2014, 9, e104275.	2.5	77
129	Managing Terrorism or Accidental Nuclear Errors, Preparing for Iodine-131 Emergencies: A Comprehensive Review. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 4158-4200.	2.6	23
130	Neurophysiological Measures and Alcohol Use Disorder (AUD): Hypothesizing Links between Clinical Severity Index and Molecular Neurobiological Patterns. <i>Journal of Addiction Research &amp; Therapy</i> , 2014, 05, .	0.2	7
131	Buprenorphine Response as a Function of Neurogenetic Polymorphic Antecedents: Can Dopamine Genes Affect Clinical Outcomes in Reward Deficiency Syndrome (RDS)?. <i>Journal of Addiction Research &amp; Therapy</i> , 2014, 05, .	0.2	21
132	A Multi-Locus Approach to Treating Fibromyalgia by Boosting Dopaminergic Activity in the Meso-Limbic System of the Brain. <i>Journal of Genetic Syndromes &amp; Gene Therapy</i> , 2014, 05, 213.	0.2	2
133	Dopaminergic Neurogenetics of Sleep Disorders in Reward Deficiency Syndrome (RDS). , 2014, 03, 126.		8
134	Can Genetic Testing Coupled with Enhanced Dopaminergic Activation Reduce Recidivism Rates in the Workers Compensation Legacy Cases?. <i>Journal of Alcoholism and Drug Dependence</i> , 2014, 02, .	0.2	7
135	Low Dopamine Function in Attention Deficit/Hyperactivity Disorder: Should Genotyping Signify Early Diagnosis in Children?. <i>Postgraduate Medicine</i> , 2014, 126, 153-177.	2.0	61
136	Drug Abuse Relapse Rates Linked to Level of Education: Can We Repair Hypodopaminergic-Induced Cognitive Decline With Nutrient Therapy?. <i>Physician and Sportsmedicine</i> , 2014, 42, 130-145.	2.1	10
137	Genetic Addiction Risk Score (GARS): Molecular Neurogenetic Evidence for Predisposition to Reward Deficiency Syndrome (RDS). <i>Molecular Neurobiology</i> , 2014, 50, 765-796.	4.0	157
138	"Cold" X5 Hairlaser, used to treat male androgenic alopecia and hair growth: an uncontrolled pilot study. <i>BMC Research Notes</i> , 2014, 7, 103.	1.4	17
139	Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior. <i>Medical Hypotheses</i> , 2014, 82, 606-614.	1.5	14
140	Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS) as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric. <i>Journal of Behavioral Addictions</i> , 2014, 3, 149-156.	3.7	119
141	Menopause Analytical Hormonal Correlate Outcome Study (MAHCOS) and the Association to Brain Electrophysiology (P300) in a Clinical Setting. <i>PLoS ONE</i> , 2014, 9, e105048.	2.5	7
142	The Genetics of Problem and Pathological Gambling: A Systematic Review. <i>Current Pharmaceutical Design</i> , 2014, 20, 3993-3999.	1.9	57
143	Dopamine and glucose, obesity, and reward deficiency syndrome. <i>Frontiers in Psychology</i> , 2014, 5, 919.	2.1	155
144	Hypothesizing Darkness Induced Alcohol Intake Linked to Dopaminergic Regulation of Brain Function. <i>Psychology</i> , 2014, 05, 282-288.	0.5	9

#	ARTICLE	IF	CITATIONS
145	Hypothesizing that designer drugs containing cathinones (‘‘bath salts’’) have profound neuro-inflammatory effects and dangerous neurotoxic response following human consumption. <i>Medical Hypotheses</i> , 2013, 81, 450-455.	1.5	20
146	A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer. <i>BMC Genomics</i> , 2013, 14, S5.	2.8	22
147	Nutrition Programs Enhance Exercise Effects on Body Composition and Resting Blood Pressure. <i>Physician and Sportsmedicine</i> , 2013, 41, 85-91.	2.1	6
148	Molecular Neurobiology of Addiction Recovery. <i>SpringerBriefs in Neuroscience</i> , 2013, , .	0.1	5
149	Hypothesising that salts of iodine, strontium and caesium reverse ageing induced by nuclear radiation. <i>International Journal of Low Radiation</i> , 2013, 9, 38.	0.1	0
150	Hypothesizing repetitive paraphilia behavior of a medication refractive Tourette’s syndrome patient having rapid clinical attenuation with KB220Z-nutrigenomic amino-acid therapy (NAAT). <i>Journal of Behavioral Addictions</i> , 2013, 2, 117-124.	3.7	20
151	Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence. <i>Journal of Addiction Research &amp; Therapy</i> , 2013, 04, 1000163.	0.2	26
152	Neuro-Genetics of Reward Deficiency Syndrome (Rds) as the Root Cause of ‘‘Addiction Transfer’’: A New Phenomena Common after Bariatric Surgery. <i>Journal of Genetic Syndromes &amp; Gene Therapy</i> , 2013, 04, .	0.2	42
153	Quantitative Electroencephalography Analysis (qEEG) of Neuro-Electro- Adaptive Therapy 12, [NEAT12] Up-Regulates Cortical Potentials in an Alcoholic during Protracted Abstinence: Putative Anti-Craving Implications. <i>Journal of Addiction Research &amp; Therapy</i> , 2013, 05, 1-7.	0.2	10
154	Genospirituality: Our Beliefs, Our Genomes, and Addictions. <i>Journal of Addiction Research &amp; Therapy</i> , 2013, 04, .	0.2	5
155	Evoked Potentials and Neuropsychological Tests Validate Positron Emission Topography (PET) Brain Metabolism in Cognitively Impaired Patients. <i>PLoS ONE</i> , 2013, 8, e55398.	2.5	11
156	Long Term Suboxone, Emotional Reactivity As Measured by Automatic Detection in Speech. <i>PLoS ONE</i> , 2013, 8, e69043.	2.5	73
157	Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms. <i>Journal of Addiction Research &amp; Therapy</i> , 2013, 03, 139.	0.2	65
158	Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note. <i>Journal of Addiction Research &amp; Therapy</i> , 2013, 04, .	0.2	72
159	Declinol, a Complex Containing Kudzu, Bitter Herbs (Gentian, Tangerine Peel)and Bupleurum, Significantly Reduced Alcohol Use Disorders Identification Test (AUDIT) Scores in Moderate to Heavy Drinkers: A Pilot Study. <i>Journal of Addiction Research &amp; Therapy</i> , 2013, 04, .	0.2	9
160	Addiction Research and Therapy in the 21st Century: Providing a Forum for Evidence -Based Addiction Medicine. <i>Journal of Addiction Research &amp; Therapy</i> , 2013, 04, .	0.2	1
161	Preliminary Hormonal Correlations in Female Patients as a Function of Somatic and Neurological Symptom Clusters: An Exploratory Development of a Multi-Hormonal Map for Bio-Identical Replacement Therapy (MHRT). <i>Journal of Genetic Syndromes &amp; Gene Therapy</i> , 2013, 04, .	0.2	0
162	&#x201C;Liking&#x201D; and &#x201C;Wanting&#x201D; Linked to Reward Deficiency Syndrome (RDS): Hypothesizing Differential Responsivity in Brain Reward Circuitry. <i>Current Pharmaceutical Design</i> , 2012, 18, 113-118.	1.9	194

#	ARTICLE	IF	CITATIONS
163	Correlation of the Taq1 dopamine D2 receptor gene and percent body fat in obese and screened control subjects: A preliminary report. <i>Food and Function</i> , 2012, 3, 40-48.	4.6	82
164	Early Intervention of Intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (NAAT) Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study. <i>Journal of Psychoactive Drugs</i> , 2012, 44, 398-409.	1.7	21
165	The Addictive Brain: All Roads Lead to Dopamine. <i>Journal of Psychoactive Drugs</i> , 2012, 44, 134-143.	1.7	138
166	Sex, Drugs, and Rock & Roll: Hypothesizing Common Mesolimbic Activation as a Function of Reward Gene Polymorphisms. <i>Journal of Psychoactive Drugs</i> , 2012, 44, 38-55.	1.7	68
167	Neuropsychopharmacology and Neurogenetic Aspects of Executive Functioning: Should Reward Gene Polymorphisms Constitute a Diagnostic Tool to Identify Individuals at Risk for Impaired Judgment?. <i>Molecular Neurobiology</i> , 2012, 45, 298-313.	4.0	28
168	Neurogenetics and Epigenetics in Impulsive Behaviour: Impact on Reward Circuitry. <i>Journal of Genetic Syndromes &amp; Gene Therapy</i> , 2012, 03, 1000115.	0.2	31
169	Diagnosis and Healing In Veterans Suspected of Suffering from Post- Traumatic Stress Disorder (PTSD) Using Reward Gene Testing and Reward Circuitry Natural Dopaminergic Activation. <i>Journal of Genetic Syndromes &amp; Gene Therapy</i> , 2012, 03, 1000116.	0.2	19
170	Neuropsychiatric Genetics of Happiness, Friendships, and Politics: Hypothesizing Homophily (‘‘Birds of a Feather Stick Together’’) in the Social Network. <i>Journal of Genetic Syndromes &amp; Gene Therapy</i> , 2012, 03, .	0.2	15
171	Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: A hypothesis. <i>Medical Hypotheses</i> , 2011, 76, 576-584.	1.5	39
172	Enhancement of ethanol-induced withdrawal convulsions by blockade of 5-hydroxytryptamine receptors. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 28, 832-835.	2.4	22
173	Generational Association Studies of Dopaminergic Genes in Reward Deficiency Syndrome (RDS) Subjects: Selecting Appropriate Phenotypes for Reward Dependence Behaviors. <i>International Journal of Environmental Research and Public Health</i> , 2011, 8, 4425-4459.	2.6	106
174	Can the Chronic Administration of the Combination of Buprenorphine and Naloxone Block Dopaminergic Activity Causing Anti-reward and Relapse Potential?. <i>Molecular Neurobiology</i> , 2011, 44, 250-268.	4.0	27
175	Reward Circuitry Dopaminergic Activation Regulates Food and Drug Craving Behavior. <i>Current Pharmaceutical Design</i> , 2011, 17, 1158-1167.	1.9	97
176	Neurogenetics and Clinical Evidence for the Putative Activation of the Brain Reward Circuitry by a Neuroadaptagen: Proposing an Addiction Candidate Gene Panel Map. <i>Journal of Psychoactive Drugs</i> , 2011, 43, 108-127.	1.7	47
177	Epigenetics in Developmental Disorder: ADHD and Endophenotypes. <i>Journal of Genetic Syndromes &amp; Gene Therapy</i> , 2011, 2, .	0.2	52
178	H-Wave® effects on blood flow and angiogenesis in longitudinal studies in rats. <i>Journal of Surgical Orthopaedic Advances</i> , 2011, 20, 255-9.	0.1	4
179	Healing enhancement of chronic venous stasis ulcers utilizing H-WAVE® device therapy: a case series. <i>Cases Journal</i> , 2010, 3, 54.	0.4	5
180	Adult growth hormone deficiency treatment with a combination of growth hormone and insulin-like growth factor-1 resulting in elevated sustainable insulin-like growth factor-1 and insulin-like growth factor binding protein 3 plasma levels: a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 305.	0.8	2

#	ARTICLE	IF	CITATIONS
181	Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 681.	2.2	11
182	Acute Intravenous Synaptamine Complex Variant KB220a, $\zeta$ $\hat{c}$ $\hat{c}$ Normalizes $\hat{c}$ Neurological Dysregulation in Patients during Protracted Abstinence from Alcohol and Opiates as Observed Using Quantitative Electroencephalographic and Genetic Analysis for Reward Polymorphisms: Part 1, Pilot Study with 2 Case Reports. <i>Postgraduate Medicine</i> , 2010, 122, 188-213.	2.0	47
183	Overcoming qEEG Abnormalities and Reward Gene Deficits during Protracted Abstinence in Male Psychostimulant and Polydrug Abusers Utilizing Putative Dopamine D <sub>2</sub> Agonist Therapy: Part 2. <i>Postgraduate Medicine</i> , 2010, 122, 214-226.	2.0	119
184	Weight Gain Is Associated with Reduced Striatal Response to Palatable Food. <i>Journal of Neuroscience</i> , 2010, 30, 13105-13109.	3.6	336
185	Do dopaminergic gene polymorphisms affect mesolimbic reward activation of music listening response? Therapeutic impact on Reward Deficiency Syndrome (RDS). <i>Medical Hypotheses</i> , 2010, 74, 513-520.	1.5	41
186	Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability. <i>Current Neuropharmacology</i> , 2010, 8, 335-358.	2.9	49
187	Neurogenetics of Dopaminergic Receptor Supersensitivity in Activation of Brain Reward Circuitry and Relapse: Proposing $\hat{c}$ Deprivation-Amplification Relapse Therapy $\hat{c}$ (DART). <i>Postgraduate Medicine</i> , 2009, 121, 176-196.	2.0	70
188	Repetitive H-Wave $\hat{c}$ device stimulation and program induces significant increases in the range of motion of post operative rotator cuff reconstruction in a double-blinded randomized placebo controlled human study. <i>BMC Musculoskeletal Disorders</i> , 2009, 10, 132.	1.9	15
189	Preliminary investigation of plasma levels of sex hormones and human growth factor(s), and P300 latency as correlates to cognitive decline as a function of gender. <i>BMC Research Notes</i> , 2009, 2, 126.	1.4	9
190	H $\hat{c}$ Wave $\hat{c}$ induces arteriolar vasodilation in rat striated muscle via nitric oxide $\hat{c}$ mediated mechanisms. <i>Journal of Orthopaedic Research</i> , 2009, 27, 1248-1251.	2.3	10
191	Age-related increases in parathyroid hormone may be antecedent to both osteoporosis and dementia. <i>BMC Endocrine Disorders</i> , 2009, 9, 21.	2.2	12
192	Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions. <i>Medical Hypotheses</i> , 2009, 72, 14-22.	1.5	80
193	Nutrigenomic targeting of carbohydrate craving behavior: Can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map?. <i>Medical Hypotheses</i> , 2009, 73, 427-434.	1.5	66
194	The H-Wave $\hat{c}$ device is an effective and safe non-pharmacological analgesic for chronic pain: a meta-analysis. <i>Advances in Therapy</i> , 2008, 25, 644-657.	2.9	20
195	LG839: Anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome. <i>Advances in Therapy</i> , 2008, 25, 894-913.	2.9	47
196	Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. <i>Theoretical Biology and Medical Modelling</i> , 2008, 5, 24.	2.1	163
197	Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPAR $\hat{c}$ and Leptin genes and up-regulation of the adiponectin gene. <i>Lipids in Health and Disease</i> , 2008, 7, 44.	3.0	44
198	Hypothesizing that Marijuana Smokers are at a Significantly Lower Risk of Carcinogenicity Relative to Tobacco-Non-Marijuana Smokers: Evidenced Based on Statistical Reevaluation of Current Literature. <i>Journal of Psychoactive Drugs</i> , 2008, 40, 263-272.	1.7	9

#	ARTICLE	IF	CITATIONS
199	The H-Wave® Device Induces NO-dependent Augmented Microcirculation and Angiogenesis, Providing Both Analgesia and Tissue Healing in Sports Injuries. <i>Physician and Sportsmedicine</i> , 2008, 36, 103-114.	2.1	19
200	Attention-deficit-hyperactivity disorder and reward deficiency syndrome. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 893.	2.2	140
201	Genotrim®, a DNA-customized nutrigenomic product, targets genetic factors of obesity: Hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). <i>Medical Hypotheses</i> , 2007, 68, 844-852.	1.5	76
202	Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: A hypothesis. <i>Medical Hypotheses</i> , 2007, 69, 1054-1060.	1.5	51
203	Gene Narcotic Attenuation Program attenuates substance use disorder, a clinical subtype of reward deficiency syndrome. <i>Advances in Therapy</i> , 2007, 24, 402-414.	2.9	27
204	Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: Evidence supported by structural equation modeling (SEM) parameter estimates. <i>Age</i> , 2007, 29, 55-67.	3.0	7
205	Synaptamine (SG8839), An Amino-Acid Enkephalinase Inhibition Nutraceutical Improves Recovery of Alcoholics, A Subtype of Reward Deficiency Syndrome (RDS). <i>Trends in Applied Sciences Research</i> , 2007, 2, 132-138.	0.4	20
206	DNA based customized nutraceutical gene therapy utilizing a genoscore: A hypothesized paradigm shift of a novel approach to the diagnosis, stratification, prognosis and treatment of inflammatory processes in the human. <i>Medical Hypotheses</i> , 2006, 66, 1008-1018.	1.5	9
207	Delayed P300 latency correlates with abnormal Test of Variables of Attention (TOVA) in adults and predicts early cognitive decline in a clinical setting. <i>Advances in Therapy</i> , 2006, 23, 582-600.	2.9	21
208	H-wave®, a nonpharmacologic alternative for the treatment of patients with chronic soft tissue inflammation and neuropathic pain: A preliminary statistical outcome study. <i>Advances in Therapy</i> , 2006, 23, 446-455.	2.9	12
209	Reward deficiency syndrome in obesity: A preliminary cross-sectional trial with a genotrim variant. <i>Advances in Therapy</i> , 2006, 23, 1040-1051.	2.9	45
210	The H-Wave® small muscle fiber stimulator, a nonpharmacologic alternative for the treatment of chronic soft-tissue injury and neuropathic pain: an extended population observational study. <i>Advances in Therapy</i> , 2006, 23, 739-749.	2.9	13
211	Neurogenetic interactions and aberrant behavioral co-morbidity of attention deficit hyperactivity disorder (ADHD): dispelling myths. <i>Theoretical Biology and Medical Modelling</i> , 2005, 2, 50.	2.1	20
212	Innate properties of H-Wave® device, a small fiber stimulator provides the basis for a paradigm shift of electro-therapeutic treatment of pain with increased functional restoration associated with human neuropathies by affecting tissue circulation: a hypothesis. <i>Medical Hypotheses</i> , 2005, 64, 1066-1067.	1.5	10
213	Are dopaminergic genes involved in a predisposition to pathological aggression?. <i>Medical Hypotheses</i> , 2005, 65, 703-707.	1.5	175
214	Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. <i>Medical Hypotheses</i> , 2004, 63, 538-548.	1.5	49
215	P300 (Latency) Event-Related Potential: An Accurate Predictor of Memory Impairment. <i>Clinical EEG (electroencephalography)</i> , 2003, 34, 124-139.	0.9	45
216	Reward deficiency syndrome: genetic aspects of behavioral disorders. <i>Progress in Brain Research</i> , 2000, 126, 325-341.	1.4	535



#	ARTICLE	IF	CITATIONS
217	The Reward Deficiency Syndrome: A Biogenetic Model for the Diagnosis and Treatment of Impulsive, Addictive and Compulsive Behaviors. <i>Journal of Psychoactive Drugs</i> , 2000, 32, 1-112.	1.7	794
218	Enhancement of Attention Processing by Kantrollâ„¢ in Healthy Humans: A Pilot Study. <i>Clinical EEG (electroencephalography)</i> , 1997, 28, 68-75.	0.9	28
219	Clinical evidence for effectiveness of Phencalâ„¢ in maintaining weight loss in an open-label, controlled, 2-year study. <i>Current Therapeutic Research</i> , 1997, 58, 745-763.	1.2	15
220	Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 297-305.	5.7	138
221	Substance Use Disorder Exacerbates Brain Electrophysiological Abnormalities in a Psychiatrically-III Population. <i>Clinical EEG (electroencephalography)</i> , 1996, 27, 5-28.	0.9	19
222	Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. <i>Pharmacogenetics and Genomics</i> , 1995, 5, 121-141.	5.7	281
223	Prolonged P300 latency in a neuropsychiatric population with the D2 Dopamine receptor A1 allele. <i>Pharmacogenetics and Genomics</i> , 1994, 4, 313-322.	5.7	49
224	Allelic association of the D2 dopamine receptor gene with cocaine dependence. <i>Drug and Alcohol Dependence</i> , 1993, 33, 271-285.	3.2	244
225	Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. <i>Alcohol</i> , 1991, 8, 409-416.	1.7	216
226	Neurodynamics of Relapse Prevention: A Neuronutrient Approach to Outpatient DUI Offenders. <i>Journal of Psychoactive Drugs</i> , 1990, 22, 173-187.	1.7	51
227	Allelic Association of Human Dopamine D2 Receptor Gene in Alcoholism. <i>JAMA - Journal of the American Medical Association</i> , 1990, 263, 2055.	7.4	748
228	Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: Double-blind placebo-controlled study of the nutritional adjunct SAAVEâ„¢. <i>Alcohol</i> , 1988, 5, 481-493.	1.7	66
229	Improvement of Inpatient Treatment of the Alcoholic as a Function of Neurotransmitter Restoration: A Pilot Study. <i>Substance Use and Misuse</i> , 1988, 23, 991-998.	0.6	33
230	Improvement of Cocaine-Induced Neuromodulator Deficits by the Neuronutrient Tropamineâ„¢. <i>Journal of Psychoactive Drugs</i> , 1988, 20, 315-331.	1.7	24
231	Enkephalinase inhibition: Regulation of ethanol intake in genetically predisposed mice. <i>Alcohol</i> , 1987, 4, 449-456.	1.7	93
232	Ethanol intoxication as function of genotype dependent responses in three inbred mice strains. <i>Pharmacology Biochemistry and Behavior</i> , 1982, 16, 13-15.	2.9	56
233	Holism: A Social Pharmacological Approach to Drug-Seeking Behavior. <i>Journal of Psychoactive Drugs</i> , 1981, 13, 369-371.	1.7	2
234	In Vivo Formation of Isoquinoline Alkaloids: Effect of Time and Route of Administration of Ethanol. <i>Advances in Experimental Medicine and Biology</i> , 1980, 126, 73-86.	1.6	7



#	ARTICLE	IF	CITATIONS
235	Opiate-like activity of salsolinol on the electrically stimulated guinea pig ileum. <i>Life Sciences</i> , 1979, 25, 2205-2210.	4.3	41
236	Acupuncture as a Common Mode of Treatment for Drug Dependence: Possible Neurochemical Mechanisms. <i>Journal of Psychedelic Drugs</i> , 1978, 10, 105-115.	0.3	7
237	Putative Role of Isoquinoline Alkaloids in Alcoholism: A Link to Opiates. <i>Alcoholism: Clinical and Experimental Research</i> , 1978, 2, 113-120.	2.4	57
238	Identification of an Isoquinoline Alkaloid after Chronic Exposure to Ethanol. <i>Alcoholism: Clinical and Experimental Research</i> , 1978, 2, 133-137.	2.4	53
239	Drugs: Have It Your Way or The Burger King Syndrome. <i>Journal of Psychedelic Drugs</i> , 1977, 9, 81-82.	0.3	0
240	Enhancement of Alcohol Withdrawal Convulsions in Mice by Haloperidol. <i>Clinical Toxicology</i> , 1976, 9, 427-434.	0.5	43
241	Morphine Withdrawal Reactions in Male and Female Mice. <i>American Journal of Drug and Alcohol Abuse</i> , 1976, 3, 363-368.	2.1	12
242	Determination of Drugs in Biologic Specimens-A Review. <i>Clinical Toxicology</i> , 1974, 7, 477-495.	0.5	6
243	Dopaminergic and other genes related to reward induced overeating, Bulimia, Anorexia Nervosa, and Binge eating. <i>Expert Review of Precision Medicine and Drug Development</i> , 0, , 1-17.	0.7	0